 The purpose of this study is to compare long-term safety and tolerability of stavudine d4T extended release ER versus conventional immediate release IR formulations, each in combination with lamivudine 3TC and efavirenz EFV in subjects who have completed Bristol-Myers Squibb BMS studies AI455-096 and AI455-099. 